Unité Mixte INSERM 564, Bâtiment Monteclair, 4 rue Larrey, 49933 Angers Cedex 09, France.
J Biol Chem. 2010 Jan 29;285(5):3470-7. doi: 10.1074/jbc.M109.049189. Epub 2009 Nov 17.
Interleukin (IL)-31 is a recently described cytokine, preferentially produced by T helper 2 lymphocytes and associated with skin diseases, such as atopic dermatitis. IL-31 is a member of the four alpha-helix bundle cytokine family and is related to the IL-6 subgroup. Its heterodimeric membrane receptor is composed of the gp130-like receptor (GPL) subunit associated to the oncostatin M receptor subunit. We identified critical amino acids implicated in the ligand receptor interaction by computational analysis combined with site-directed mutagenesis. Six IL-31 residues selected for their putative involvement in cytokine receptor contact sites were alanine-substituted, and the corresponding proteins were expressed in mammalian and bacterial systems. Biochemical, membrane binding, cell signaling, and cell proliferation analyses showed that mutation E44A, E106A, or H110A abolished IL-31 binding to GPL and the subsequent signaling events. A second ligand receptor-binding site involved Lys(134), with alanine substitution leading to a protein that still binds GPL, but is unable to recruit the second receptor subunit and the subsequent signaling pathways. The results indicate that IL-31 recognizes its receptor complex through two different binding sites, and we propose a three-dimensional model for IL-31.
白细胞介素 (IL)-31 是一种最近描述的细胞因子,主要由辅助性 T 细胞 2 淋巴细胞产生,并与皮肤疾病有关,如特应性皮炎。IL-31 是四螺旋束细胞因子家族的成员,与白细胞介素 6 亚群有关。其异二聚体膜受体由 gp130 样受体 (GPL) 亚基与肿瘤坏死因子受体亚基组成。我们通过计算分析结合定点诱变鉴定了与配体受体相互作用相关的关键氨基酸。选择了六个可能参与细胞因子受体接触位点的 IL-31 残基进行丙氨酸取代,并在哺乳动物和细菌系统中表达了相应的蛋白质。生化、膜结合、细胞信号转导和细胞增殖分析表明,E44A、E106A 或 H110A 突变消除了 IL-31 与 GPL 的结合以及随后的信号事件。第二个配体受体结合位点涉及赖氨酸 (134),丙氨酸取代导致仍能与 GPL 结合但不能募集第二个受体亚基和随后的信号通路的蛋白质。结果表明,IL-31 通过两个不同的结合位点识别其受体复合物,我们提出了 IL-31 的三维模型。